Atrial Fibrillation Market Report 2026

The atrial fibrillation market size has grown rapidly in recent years. It will grow from $15.1 billion in 2025 to $17.1 billion in 2026 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing prevalence of atrial fibrillation in aging populations, improved access to cardiac diagnostic technologies, wider availability of anticoagulant therapies, expansion of electrophysiology labs, growing awareness of stroke prevention.

The atrial fibrillation market size is expected to see rapid growth in the next few years. It will grow to $27.88 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to increasing demand for personalized arrhythmia treatment, rising adoption of wearable cardiac monitoring devices, expansion of hybrid treatment approaches, growing investments in electrophysiology infrastructure, increasing focus on long-term rhythm management outcomes. Major trends in the forecast period include increasing adoption of catheter ablation procedures, rising use of advanced cardiac mapping systems, growing preference for minimally invasive treatments, expansion of pharmacological rhythm control therapies, enhanced focus on early diagnosis and monitoring.

The rising prevalence of cardiovascular diseases is anticipated to propel the growth of the atrial fibrillation market. Cardiovascular diseases are a group of disorders that impact the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and arrhythmias, which pose a significant threat to overall cardiovascular health. The increase in cardiovascular conditions highlights the growing need for advanced diagnostic and treatment solutions, boosting the atrial fibrillation market as healthcare systems and industries address the mounting challenges associated with the rising incidence of these diseases. For example, in October 2024, the CDC (Centers for Disease Control and Prevention), a U.S.-based government agency, reported that in 2023, 919,032 people died from cardiovascular disease, which is equivalent to 1 in every 3 deaths. Additionally, approximately 805,000 people in the United States experience a heart attack each year. Consequently, the high global burden of cardiovascular diseases is expected to drive the atrial fibrillation market.

Major companies in the atrial fibrillation market are introducing innovative products and solutions, such as patient-focused clinical decision support tools, to enhance their market presence. Clinical decision support tools (CDST) are software or electronic systems designed to aid healthcare professionals in making informed and timely decisions regarding patient care. These tools are created to integrate relevant clinical information from multiple sources. For example, in August 2023, GE HealthCare, a US-based multinational medical technology company, launched CardioVisio, a patient-centered clinical decision support tool aimed at helping doctors provide evidence-based clinical decisions aligned with current atrial fibrillation guidelines and visualize longitudinal data from various sources relevant to disease progression. CardioVisio for atrial fibrillation can support cardiologists by streamlining clinician image interpretation and offering a comprehensive view of the patient’s heart history and healthcare journey, including previous diagnoses, prescribed medications, interventions, and comorbidities.

In February 2025, Novartis, a Switzerland-based pharmaceutical company, acquired Anthos Therapeutics, Inc., for $925 million upfront, with potential milestone payments reaching up to $2.15 billion. Through this acquisition, Novartis intends to strengthen its atrial fibrillation treatment portfolio by incorporating Anthos’s FXI-inhibiting therapy, abelacimab, aimed at stroke prevention in AF patients. Anthos Therapeutics, Inc. is a U.S.-based biopharmaceutical company that develops abelacimab, a monoclonal antibody targeting Factor XI to prevent stroke and systemic embolism in patients with atrial fibrillation.

Major companies operating in the atrial fibrillation market are AtriCure Inc, Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Johnson & Johnson, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Sanofi SA, Bayer AG, Pfizer Inc, Daiichi Sankyo Company Limited, AstraZeneca PLC, Biotronik SE & Co KG, Kardium Inc, Acutus Medical Inc, Apama Medical Inc, CardioFocus Inc, AliveCor Inc, iRhythm Technologies Inc, BioSig Technologies Inc.

North America was the largest region in the atrial fibrillation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the atrial fibrillation market report forecast period. The regions covered in the atrial fibrillation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atrial fibrillation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the atrial fibrillation market by increasing costs of imported ablation catheters, electrophysiology mapping systems, implantable cardiac devices, and specialized medical electronics. Hospitals and electrophysiology centers in North America and Europe are most affected due to reliance on imported high-value devices, while Asia-Pacific faces cost pressures on advanced treatment adoption. These tariffs are raising procedural costs and capital expenditure requirements. At the same time, they are encouraging local manufacturing of cardiac devices, regional supplier partnerships, and increased investment in domestically produced electrophysiology technologies.

The atrial fibrillation market research report is one of a series of new reports that provides atrial fibrillation market statistics, including atrial fibrillation industry global market size, regional shares, competitors with a atrial fibrillation market share, detailed atrial fibrillation market segments, market trends and opportunities, and any further data you may need to thrive in the atrial fibrillation industry. This atrial fibrillation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atrial fibrillation is a heart disorder caused by a disruption in the normal sequence of electrical impulses, which alters the rate or rhythm of the heartbeat and originates in the upper chambers of the heart (atria). These electrical impulses may be too fast, too slow, or occur irregularly, leading to an uneven heartbeat.

The main types of atrial fibrillation include surgical and non-surgical approaches. Surgical atrial fibrillation treatment involves a procedure in which a patient receives an electrical shock on the exterior of the chest to regulate the heartbeat, using either paddles or patches. Technologies such as radiofrequency, laser, cryotherapy, and others are employed for treatments including pharmacological, non-pharmacological, maze surgery, and electrical cardioversion. These treatments are utilized by various end-users, including hospitals, electrophysiology labs, and ambulatory surgical centers.

The atrial fibrillation market includes revenues earned by entities from treatment for sinus bradycardia, premature atrial contractions (PACS), wandering atrial pacemakers, atrial tachycardia, multifocal atrial tachycardia, atrial flutter, and atrial fibrillation (AFib). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.